Emerging treatments
Temozolomide
Temozolomide, a second generation alkylating agent of the imidazotetrazine class, may be the only effective chemotherapeutic agent available for aggressive, progressive, and recurrent atypical pituitary adenomas and carcinomas resistant to conventional multimodal treatment. However, it should be used with caution in view of the lack of controlled trials.[73] Compared with functioning pituitary tumors, clinically nonfunctional pituitary adenomas exhibit a lower response rate (45% vs 17%).[79]
Use of this content is subject to our disclaimer